Ramsay Health Care Limited

DB:RMY Stock Report

Market Cap: €5.4b

Ramsay Health Care Valuation

Is RMY undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RMY when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: RMY (€23) is trading below our estimate of fair value (€59.23)

Significantly Below Fair Value: RMY is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RMY?

Key metric: As RMY is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for RMY. This is calculated by dividing RMY's market cap by their current earnings.
What is RMY's PE Ratio?
PE Ratio34.1x
EarningsAU$253.90m
Market CapAU$8.65b

Price to Earnings Ratio vs Peers

How does RMY's PE Ratio compare to its peers?

The above table shows the PE ratio for RMY vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average21x
RHK RHÖN-KLINIKUM
18.9x7.5%€850.1m
M12 M1 Kliniken
17.9x17.5%€300.6m
LIK LIMES Schlosskliniken
22.9xn/a€98.5m
AFX Carl Zeiss Meditec
24.1x16.3%€5.1b
RMY Ramsay Health Care
34.1x19.3%€8.7b

Price-To-Earnings vs Peers: RMY is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the peer average (21x).

Price to Earnings Ratio vs Industry

How does RMY's PE Ratio compare vs other companies in the European Healthcare Industry?

2 CompaniesPrice / EarningsEstimated GrowthMarket Cap
RMY 34.1xIndustry Avg. 18.2xNo. of Companies10PE01020304050+
2 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: RMY is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the European Healthcare industry average (18.2x).

Price to Earnings Ratio vs Fair Ratio

What is RMY's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RMY PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio34.1x
Fair PE Ratio26x

Price-To-Earnings vs Fair Ratio: RMY is expensive based on its Price-To-Earnings Ratio (34.1x) compared to the estimated Fair Price-To-Earnings Ratio (26x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RMY forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Current€23.00
€27.94
+21.5%
12.0%€38.05€24.55n/a14
Nov ’25€23.40
€28.29
+20.9%
11.8%€38.41€24.78n/a14
Oct ’25€25.80
€28.15
+9.1%
12.4%€37.68€24.31n/a15
Sep ’25€25.00
€29.67
+18.7%
12.6%€37.97€24.50n/a15
Aug ’25€27.80
€32.94
+18.5%
11.0%€40.99€29.78n/a15
Jul ’25€28.60
€35.40
+23.8%
10.4%€42.34€31.13n/a16
Jun ’25€28.60
€34.82
+21.7%
10.4%€41.64€30.62n/a16
May ’25€31.60
€34.56
+9.4%
9.6%€41.08€30.20n/a16
Apr ’25€33.80
€34.56
+2.3%
9.6%€41.08€30.20n/a16
Mar ’25€32.40
€34.63
+6.9%
9.2%€40.90€30.07n/a16
Feb ’25€30.40
€34.12
+12.3%
9.7%€41.40€30.14n/a15
Jan ’25€32.20
€34.02
+5.7%
12.5%€41.70€25.75n/a15
Dec ’24€29.00
€33.57
+15.7%
12.5%€41.14€25.41n/a15
Nov ’24€29.00
€33.95
+17.1%
12.5%€40.76€25.77€23.4015
Oct ’24€31.60
€34.13
+8.0%
13.0%€42.42€25.90€25.8016
Sep ’24€30.60
€33.81
+10.5%
12.6%€41.79€25.52€25.0017
Aug ’24€35.60
€38.43
+8.0%
9.0%€45.50€32.27€27.8017
Jul ’24€34.20
€39.74
+16.2%
8.2%€46.02€32.89€28.6017
Jun ’24€35.00
€40.31
+15.2%
7.6%€46.27€33.07€28.6017
May ’24€38.60
€42.62
+10.4%
6.2%€47.58€37.17€31.6017
Apr ’24€41.00
€42.83
+4.5%
5.8%€47.83€39.05€33.8017
Mar ’24€42.40
€43.89
+3.5%
6.6%€49.46€37.63€32.4016
Feb ’24€42.80
€43.47
+1.6%
6.7%€48.83€38.41€30.4015
Jan ’24€41.20
€42.39
+2.9%
6.9%€48.06€37.81€32.2015
Dec ’23€43.00
€42.64
-0.8%
6.8%€48.24€37.95€29.0015
Nov ’23€37.80
€44.81
+18.5%
8.1%€52.94€38.51€29.0016

Analyst Forecast: Target price is more than 20% higher than the current share price and analysts are within a statistically confident range of agreement.

Discover undervalued companies

Fagron

€1.3b

A pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide.

4A5

€18.12

7D

-3.1%

1Y

5.2%

Shandong Weigao Group Medical Polymer

HK$20.6b

Engages in the research and development, production, wholesale, and sale of medical devices in the People’s Republic of China.

UK2

HK$0.53

7D

-13.2%

1Y

-37.9%

LNA Santé

€243.4m

Engages in the management and operation of health establishments.

2N3

€23.45

7D

-5.6%

1Y

16.1%